• Shuttle Pharmaceutical entered definitive merger agreement to acquire Dogecoin miner United Dogecoin, which will become wholly owned subsidiary.
• Transaction backed by USD 11 million PIPE financing expected to close May 4, 2026.
• Consideration includes 8,000 shares of Series B-1 Convertible Preferred Stock, convertible at USD 1.24 into about 32,258,064 common shares, subject to stockholder approval.
• Deal also provides up to 118,038,551 pre-funded warrants tied to post-closing operational milestones, issuable only if stockholder approval is obtained.
• Post-merger board plans to appoint United Dogecoin CEO Ryan Trasolini as co-CEO alongside Christopher Cooper, with CFO Yuying Liang continuing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-020830), on May 01, 2026, and is solely responsible for the information contained therein.